
Please try another search
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement-mediated immunologic diseases; STP237G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was founded in 2007 and is based in Wan Chai, Hong Kong.
Name | Age | Since | Title |
---|---|---|---|
Frederick C. Beddingfield | 59 | 2024 | Chairman of Sagesse Bio Inc. |
Monin Ung | 54 | 2021 | Independent Chairlady |
Jiankang Zhang | 68 | 2021 | Non Executive Director |
Cheung-Hoi Yu | 70 | 2021 | Independent Non Executive Director |
Yu Shan Wong | 54 | 2025 | Independent Non-Executive Director |
Mo Han Shing | 70 | 2021 | Independent Non-Executive Director |
Hung Fai Poon | 46 | 2024 | Chief Executive Officer & Executive Director |
Yunlong Ouyang | 38 | 2025 | Non-Executive Director |
Peng Zhang | 49 | 2025 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review